KemPharm, Inc. / Fundamentals
Income statement
- Net revenue
€51.13M - Cost of goods sold
€19.38M - Gross profit
€31.75M - SG&A expenses
€79.04M - R&D expenses
€26.84M - EBITDA
-€171.58M - D&A
€680.19K - EBIT
-€134.96M - Interest expenses
-€11.11M - EBT
-€15.06M - Tax expenses
-€5.71M - Net income
-€41.35M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€61.66M - Changes in working capital
€3.42M - Operating cash flow
-€84.85M - Capex
€243.82K - Other investing cash flow
€136.92M - Net investing cash flow
-€11.62M - Total cash dividends paid
€0.00 - Issuance of common stock
€55.72M - Debt repayment
€0.00 - Other financing cash flow
€88.86M - Net financing cash flow
€132.34M - Foreign exchange effects
€158.53K - Net change in cash
€52.64M - Cash at end of period
€41.11M - Free cash flow
-€84.60M
Balance sheet
- Cash and cash equivalents
€41.11M - Cash and short-term investments
€41.11M - Total receivables
€15.74M - Inventory
€954.60K - Other current assets
€137.20M - Total current assets
€195.00M - Property, plant & equipment
€1.80M - Goodwill
€4.05M - Intangible assets
€6.08M - Long-term investments
€0.00 - Other non-current assets
€13.86M - Total non-current assets
€25.79M - Total assets
€220.80M - Accounts payable
€0.00 - Short-term debt
€452.31K - Other current liabilities
€9.33M - Total current liabilities
€24.84M - Long-term debt
€53.20M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€41.75M - Total non-current liabilities
€94.96M - Total liabilities
€119.80M - Common stock
€5.17K - Retained earnings
-€373.64M - Other equity
-€2.09M - Total equity
€101.00M - Total liabilities and shareholders' equity
€220.80M
Company information
- Market capitalization
€170.99M - Employees
24 - Enterprise Value
€537.39M
Company ratios
- Gross margin
-
62.1% Much better than peer group: -80.5% - EBITDA margin
-
-335.6% Much better than peer group: -25,969.1% - EBIT margin
-
-264.0% Much better than peer group: -26,720.3% - EBT margin
-
-29.5% Much better than peer group: -27,544.5% - Net margin
-
-80.9% Much better than peer group: -27,578.2% - ROE
-
-40.9% Better than peer group: -55.8% - ROA
-
-18.7% Much better than peer group: -60.6% - Asset turnover
-
23.2% Worse than peer group: 35.6% - FCF margin
-
-166.4% Much better than peer group: -26,163.3% - FCF yield
-49.8% - Efficiency ratio
435.6% - Net sales per employee
-
€2.13M - Net income per employee
-
-€1.72M